Acura receives $200K loan from AD Pharma; warns of possible shutdown without more funding by mid-August

ACURA PHARMACEUTICALS, INC

New $200K loan from Abuse Deterrent Pharma increases principal to $10.9M, bearing 5.25% interest.
Accrued interest ~$1.2M as of July 17, 2026; overdue amounts bear 7.5% interest.
Without additional financing by mid-August 2026, company will scale back operations, furlough/lay off employees, or seek bankruptcy.
Failure to secure funding could result in complete loss of shareholder value.
Loan proceeds used for day-to-day operations; no assurance of further financing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.